Estrogen and Progesterone Therapy and Meningiomas
Endocrinology · 01.02.2022 · 163 (2)
DOI: 10.1210/endocr/bqab259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 22.12.2021. Verfasst von Mirella Hage und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire Ambroise Paré, Service d'Endocrinologie Diabétologie et Nutrition, Assistance Publique-Hôpitaux de Paris, F-92100 Bo…. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
Meningiomas are common intracranial tumors with a female predominance. Their etiology is still poorly documented. The role of sexual hormones has long been evoked, and data have been conflicting across studies. However, a dose-dependent relationship between the incidence and growth of meningiomas and hormonal treatment with the progestin cyproterone acetate (CPA) has recently been established. CPA-associated meningiomas seem to be mainly located in the anterior and middle skull base, are more likely to be multiple, may harbor P1K3CA mutations in up to one-third of cases, and are more common with a longer duration of treatment. A similar but lower risk of meningiomas has been recently reported with the use of chlormadinone acetate and nomegestrol acetate as progestin treatments. Concerning hormonal replacement therapy (HRT) in menopausal patients, evidence from epidemiological studies seem to favor an increased risk of meningiomas in treated patients although a recent study failed to show an increased growth of meningiomas in HRT treated vs nontreated patients. Until larger studies are available, it seems wise to recommend avoiding HRT in patients with meningiomas. Evidence from published data does not seem to support an increased risk of meningiomas with oral contraceptive oral contraceptive (OR) use. Data are too scarce to conclude on fertility treatments. Based on studies demonstrating the expression of hormonal receptors in meningiomas, therapies targeting these receptors have been tried but have failed to show an overall favorable clinical outcome in meningioma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Universitaire Ambroise Paré, Service d'Endocrinologie Diabétologie et Nutrition, Assistance Publique-Hôpitaux de Paris, F-92100 Boulogne Billancourt, France.
- EA4340, Université de Versailles Saint-Quentin-en-Yvelines, UFR des Sciences de la Santé Simone Veil, F-78423 Montigny-le-Bretonneux, France.
ORCID-Profile: Mirella Hage
Zitieren
APA
Hage, M., Plesa, O., Lemaire, I., & Raffin Sanson, M. L. (2022). Estrogen and Progesterone Therapy and Meningiomas. Endocrinology, 163(2). https://doi.org/10.1210/endocr/bqab259
Vancouver
Hage M, Plesa O, Lemaire I, Raffin Sanson ML. Estrogen and Progesterone Therapy and Meningiomas. Endocrinology. 2022;163(2). doi:10.1210/endocr/bqab259
BibTeX
@article{Hage2022,
author = {Hage, Mirella and Plesa, Oana and Lemaire, Isabelle and Raffin Sanson, Marie Laure},
title = {Estrogen and Progesterone Therapy and Meningiomas},
journal = {Endocrinology},
year = {2022},
volume = {163},
number = {2},
doi = {10.1210/endocr/bqab259}
}
EUVIMED